IL6 and plasma cell myeloma: The gene set enrichment analyses (GSEAs) revealed significant upregulation of various pathways [43], including “positive regulation of interleukin-6 production” (p = 0.001); IL-6 drives myeloma cell survival and its secretion can be inhibited by lenalidomide therapy [44].